Adjuvant exemestane with ovarian suppression in premenopausal breast cancer (Q34245992)

31 July 2017

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer (English)

1 reference

31 July 2017

1 reference

29

Giuseppe Viale

1 reference

31 July 2017

12

Vered Stearns

1 reference

31 July 2017

9

Harold J Burstein

1 reference

31 July 2017

1

Olivia Pagani

1 reference

31 July 2017

32

Aron Goldhirsch

1 reference

31 July 2017

2

Meredith M Regan

1 reference

31 July 2017

28

Karin Ribi

1 reference

31 July 2017

10

Edith A Perez

1 reference

31 July 2017

33

Prudence A Francis

1 reference

31 July 2017

11

Eva Ciruelos

1 reference

31 July 2017

3

Barbara A Walley

1 reference

31 July 2017

4

Gini F Fleming

1 reference

31 July 2017

5

Marco Colleoni

1 reference

31 July 2017

6

István Láng

1 reference

31 July 2017

8

Carlo Tondini

1 reference

31 July 2017

13

Hervé R Bonnefoi

1 reference

31 July 2017

14

Silvana Martino

1 reference

31 July 2017

15

Charles E Geyer

1 reference

31 July 2017

16

Graziella Pinotti

1 reference

31 July 2017

19

Thomas Ruhstaller

1 reference

31 July 2017

20

Eric P Winer

1 reference

31 July 2017

Manuela Rabaglio-Poretti

21

object named as

Manuela Rabaglio-Poretti

1 reference

31 July 2017

23

Barbara Ruepp

1 reference

31 July 2017

24

Anita Giobbie-Hurder

1 reference

31 July 2017

25

Karen N Price

1 reference

31 July 2017

27

Weixiu Luo

1 reference

TEXT and SOFT Investigators

31 July 2017

34

object named as

TEXT and SOFT Investigators

1 reference

International Breast Cancer Study Group

31 July 2017

35

object named as

International Breast Cancer Study Group

1 reference

31 July 2017

18

Diana Crivellari

1 reference

31 July 2017

Henry L Gomez

7

1 reference

31 July 2017

Fabio Puglisi

17

1 reference

31 July 2017

Rudolf Maibach

22

1 reference

31 July 2017

Jürg Bernhard

26

1 reference

31 July 2017

Alan S Coates

30

1 reference

31 July 2017

Richard D Gelber

31

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 June 2014

1 reference

The New England Journal of Medicine

31 July 2017

1 reference

31 July 2017

371

1 reference

31 July 2017

2

1 reference

31 July 2017

107-118

1 reference

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.

31 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

Breast cancer. Clinical practice guidelines in oncology

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175521

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

6 July 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24881463

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1404037

1 reference

31 July 2017

1 reference

31 July 2017

1 reference